Nintedanib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), G-BA (Germany) and HAS (France), among others, recommended or restricted nintedanib, while CIPM (Spain), NYE METODER (Norway) and ZIN (Netherlands) did not recommend it.
Assessment has run over 11.8 years, from 20 Aug 2014 at AWMSG (Wales) to 8 Jun 2026 at SMC (Scotland).
DMC (Denmark) changed its position: recommended on 23 Feb 2022, not recommended by 23 Feb 2022.
Every one of the eight highest-volume agencies in this archive has a record for nintedanib.
Not every gap is a refusal: for nintedanib, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 13 of 49 records date from 2023 or later.
The programme is broad: 15 distinct indication wordings are recorded for nintedanib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
8 of these 49 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess nintedanib, on 20 Aug 2014; HIRA (South Korea) did not open a file until 9 Jan 2025 — an unusually long tail of 10.4 years between the earliest and latest system to look at it.
The record arrives in waves: 8 separate years each carry two or more decisions, spread across 12 years in total.
12 of the 15 agencies here assessed nintedanib more than once, PBAC (Australia) most often at 8 entries — repeat review is the norm for this molecule rather than the exception.
nintedanib has been through 15 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for nintedanib reads 20 recommended, 8 not recommended, 5 other and 5 restricted, with 11 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 14 Jan 2026 | Indication extension | SMR moderate · ASMR IV | source |
| NICE (England) | 19 Nov 2025 | NICE TA1111 | terminated appraisal | source |
| G-BA (Germany) | 7 Aug 2025 | Ofev — benefit assessment §35a | added benefit: not proven | source |
| NYE METODER (Norway) | 27 Apr 2025 | Til behandling av systemisk sklerose-assosiert interstitiell lungesykdom (SSc-ILD) hos voksne. | decision recorded | source |
| HIRA (South Korea) | 9 Jan 2025 | 1. 특발성 폐섬유증 2. 전신경화증 연관 간질성 폐질환 3. 진행성 폐섬유증 | reimbursement appropriate | source |
44 further decisions for nintedanib, across 14 agencies, are not shown here. They include the most recent record on file, 8 Jun 2026 from SMC (Scotland); its outcome is in the subscriber dataset. They link to 33 further source documents.
Related molecules
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
- ribociclib — same ATC class L01E — Antineoplastics
Coverage: 49 decisions for nintedanib from 15 agencies, 2014 to 2026. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.